sur NFL BIOSCIENCES (EPA:ALNFL)
NFL BIOSCIENCES: 2024 First-Half Business and Earnings Update
NFL Biosciences, a biopharmaceutical firm, advances its drug candidates for smoking cessation and reducing alcohol consumption. With key stages completed for NFL-101, a smoking cessation treatment, the company is now preparing for its Phase 3 trial.
Noteworthy progress has been made for NFL-301, aimed at curbing excessive alcohol consumption. NFL Biosciences extended its cash runway to Q3 2025, raising €3 million in April. This funding primarily supports Phase 3 requirements for NFL-101 and the NFL-301 development plan.
NFL Biosciences reported a net income of €(0.7) million for H1 2024, showing improvement from €(2.1) million in H1 2023. The company, still in clinical trials, aims for strategic collaborations and further advancements in its trial phases.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de NFL BIOSCIENCES